Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCG | P01275 | 5/20 | 0.63 |
| ▸ | GCGR | P47871 | 16/20 | 0.55 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.47 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.47 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.47 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.47 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.47 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.47 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.47 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.47 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268527 | 1.00 | GCG (0.63) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2269455 | 0.93 | GCGR (0.64) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2269451 | 0.93 | GCGR (0.64) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2270178 | 0.89 | GCGR (0.65) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2270185 | 0.89 | GCGR (0.65) | GCGGCGRADCY6ADCY3ADCY9 | |
| SCHEMBL2271859 | 0.85 | GCG (0.81) | GCGGCGR | |
| SCHEMBL2271866 | 0.85 | GCG (0.81) | GCGGCGR | |
| SCHEMBL2269697 | 0.84 | GCGR (0.56) | GCGGCGR | |
| SCHEMBL2269702 | 0.84 | GCGR (0.56) | GCGGCGR | |
| SCHEMBL1765408 | 0.83 | GCG (0.80) | GCGGCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | claimed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | claimed |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | REMD Biotherapeutics, Inc | 2017-05-25 | — | — | US | disclosed |
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| EP-1758859-B1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2013-07-17 | — | — | EP | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989457-B2 | Used to treat diabetic and other glucagon related metabolic disorders such as obesity, hyperglycemia, atherosclerosis, ischemic heart disease, stroke, neuropathy, and wound healing; (R,S)-Methanesulfonic acid 2-(3-methyl-4'-trifluoromethyl-biphenyl-4-yl)-propyl ester | ELI LILLY AND COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | ELI LILLY AND COMPANY | 2008-05-29 | — | — | US | disclosed |
| EP-1758859-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
| WO-2005118542-A1 | GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125468-A1 | Glucagon Receptor Antagonists, Preparation and Therapeutic Uses | GLP1R, GCGR, GIPR | GCG 5/4885GCGR 2/4885ADCY6 186/4885 |
| US-20170143673-A1 | Methods For Treating Heart Failure Using Glucagon Receptor Antagonists | GLP1R, GCGR, GIPR | GCG 5/4885GCGR 2/4885ADCY6 555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.